Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L GREENBERG

Showing results (841-850 of 881) with videos related to

Pageof 89
Sort By:
Journal of Hematology & Oncology|June 28, 2017
Clinical characteristics and outcomes according to age in lenalidomide-treated patients with RBC transfusion-dependent lower-risk MDS and del(5q)Pierre Fenaux, Aristoteles Giagounidis, Dominik Selleslag, et al.
Biorxiv : the Preprint Server for Biology|October 24, 2023
Shared and Distinct Mechanisms of UBA1 Inactivation Across Different DiseasesJason C Collins, Samuel J Magaziner, Maya English, et al.
Autism Research : Official Journal of the International Society for Autism Research|December 24, 2025
An Examination of Racial Bias in Scoring the Autism Diagnostic Observation Schedule (ADOS) Module 3: An Item Response Theory AnalysisYuen Yvonne Yu, Austin Wyman, Calliana J Faulk, et al.
Leukemia Research|October 14, 2016
KB004, a first in class monoclonal antibody targeting the receptor tyrosine kinase EphA3, in patients with advanced hematologic malignancies: Results from a phase 1 studyRonan T Swords, Peter L Greenberg, Andrew H Wei, et al.
Blood|June 23, 2012
Overexpression of IL-1 receptor accessory protein in stem and progenitor cells and outcome correlation in AML and MDSLaura Barreyro, Britta Will, Boris Bartholdy, et al.
Blood|September 26, 2007
Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5qAzra Raza, James A Reeves, Eric J Feldman, et al.
Genes, Chromosomes & Cancer|September 11, 2015
Frequency of del(12p) is commonly underestimated in myelodysplastic syndromes: Results from a German diagnostic study in comparison with an international control groupFriederike Braulke, Catharina Müller-Thomas, Katharina Götze, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|January 15, 2011
NCCN Clinical Practice Guidelines in Oncology: myelodysplastic syndromesPeter L Greenberg, Eyal Attar, John M Bennett, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 26, 2013
Role of reduced-intensity conditioning allogeneic hematopoietic stem-cell transplantation in older patients with de novo myelodysplastic syndromes: an international collaborative decision analysisJohn Koreth, Joseph Pidala, Waleska S Perez, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|July 13, 2013
Myelodysplastic syndromes: clinical practice guidelines in oncologyPeter L Greenberg, Eyal Attar, John M Bennett, et al.
Pageof 89

Showing results (841-850 of 881) with videos related to

Sort By:
Pageof 89
Journal of Hematology & Oncology|June 28, 2017
Clinical characteristics and outcomes according to age in lenalidomide-treated patients with RBC transfusion-dependent lower-risk MDS and del(5q)Pierre Fenaux, Aristoteles Giagounidis, Dominik Selleslag, et al.
Biorxiv : the Preprint Server for Biology|October 24, 2023
Shared and Distinct Mechanisms of UBA1 Inactivation Across Different DiseasesJason C Collins, Samuel J Magaziner, Maya English, et al.
Autism Research : Official Journal of the International Society for Autism Research|December 24, 2025
An Examination of Racial Bias in Scoring the Autism Diagnostic Observation Schedule (ADOS) Module 3: An Item Response Theory AnalysisYuen Yvonne Yu, Austin Wyman, Calliana J Faulk, et al.
Leukemia Research|October 14, 2016
KB004, a first in class monoclonal antibody targeting the receptor tyrosine kinase EphA3, in patients with advanced hematologic malignancies: Results from a phase 1 studyRonan T Swords, Peter L Greenberg, Andrew H Wei, et al.
Blood|June 23, 2012
Overexpression of IL-1 receptor accessory protein in stem and progenitor cells and outcome correlation in AML and MDSLaura Barreyro, Britta Will, Boris Bartholdy, et al.
Blood|September 26, 2007
Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5qAzra Raza, James A Reeves, Eric J Feldman, et al.
Genes, Chromosomes & Cancer|September 11, 2015
Frequency of del(12p) is commonly underestimated in myelodysplastic syndromes: Results from a German diagnostic study in comparison with an international control groupFriederike Braulke, Catharina Müller-Thomas, Katharina Götze, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|January 15, 2011
NCCN Clinical Practice Guidelines in Oncology: myelodysplastic syndromesPeter L Greenberg, Eyal Attar, John M Bennett, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 26, 2013
Role of reduced-intensity conditioning allogeneic hematopoietic stem-cell transplantation in older patients with de novo myelodysplastic syndromes: an international collaborative decision analysisJohn Koreth, Joseph Pidala, Waleska S Perez, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|July 13, 2013
Myelodysplastic syndromes: clinical practice guidelines in oncologyPeter L Greenberg, Eyal Attar, John M Bennett, et al.
Pageof 89